<![CDATA[Infraredx, Inc. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=32903>Mon, 20 Apr 2026 02:29:40 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Results of the PROSPECT II Natural History Study Demonstrate High-Risk Plaques Identified by NIRS+IVUS Imaging are Linked to Future Coronary Events]]>https://www.newswire.co.kr/newsRead.php?no=912305Fri, 16 Oct 2020 11:45:00 +0900<![CDATA[PROSPECT II 과거이력 연구, NIRS+IVUS 이미징을 통해 밝혀진 고위험성 플라크가 추후 관상동맥 사건과 깊은 관련이 있음 밝혀]]>https://www.newswire.co.kr/newsRead.php?no=912307Fri, 16 Oct 2020 11:45:00 +0900<![CDATA[Infraredx, a Nipro Company, Announces FDA Approval of Expanded Label Claim for the Makoto™ Intravascular Imaging System]]>https://www.newswire.co.kr/newsRead.php?no=887013Tue, 23 Apr 2019 13:50:00 +0900<![CDATA[Nipro Company 자회사 Infraredx, FDA로부터 Makoto™ 혈관 내 영상 시스템의 라벨확대 승인]]>https://www.newswire.co.kr/newsRead.php?no=887014Tue, 23 Apr 2019 13:50:00 +0900